Skip to content
HowShorted

Esperion Therapeutics, Inc. short interest in 2019

In 2019, Esperion Therapeutics, Inc.'s disclosed short interest ran from 22.01% of shares outstanding on 15 Jan 2019 to 18.15% on 31 Dec 2019, a change of -3.86 percentage points. The year's high was 22.01% on 15 Jan 2019 and its low 15.64% on 30 Apr 2019, averaging 19.03% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.11 days on 31 Oct 2019. Full history: Esperion Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Esperion Therapeutics, Inc. in 2019

2019 in figures

Start of year
22.01% (15 Jan 2019)
End of year
18.15% (31 Dec 2019)
Change
-3.86 pp
High
22.01% (15 Jan 2019)
Low
15.64% (30 Apr 2019)
Average
19.03%
Highest days to cover
17.11 (31 Oct 2019)
SEC filings marked
8

Every report in 2019

Esperion Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201922.01%5.83
31 Jan 201920.54%11.05
15 Feb 201918.82%14.91
28 Feb 201918.49%12.3110-K filed, results (8-K)
15 Mar 201920.25%8.39
29 Mar 201917.30%7.03
15 Apr 201917.49%8.30
30 Apr 201915.64%6.54
15 May 201919.32%6.2810-Q filed, results (8-K)
31 May 201920.02%12.45
14 Jun 201918.37%12.88
28 Jun 201919.52%10.27
15 Jul 201918.90%13.56
31 Jul 201920.45%13.24
15 Aug 201919.22%10.2910-Q filed, results (8-K)
30 Aug 201919.87%13.69
13 Sep 201919.91%11.01
30 Sep 201918.51%12.74
15 Oct 201917.21%14.47
31 Oct 201917.10%17.11
15 Nov 201919.82%12.5510-Q filed, results (8-K)
29 Nov 201920.25%8.09
13 Dec 201919.46%12.08
31 Dec 201918.15%11.02

See also: Esperion Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.